Prabhu Saileta, Boswell C Andrew, Leipold Douglas, Khawli Leslie A, Li Dongwei, Lu Dan, Theil Frank-Peter, Joshi Amita, Lum Bert L
Early Development Pharmacokinetic & Pharmacodynamic Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
Ther Deliv. 2011 Jun;2(6):769-91. doi: 10.4155/tde.11.41.
The therapeutic rationale of antibody conjugates is the selective delivery of a cytotoxin to tumor cells via binding and internalization of the monoclonal antibodies to a specific cell-surface antigen, thereby enhancing the therapeutic index of the cytotoxin. The key structural and functional components of an antibody conjugate are the antibody, the linker and the cytotoxin (chemical or radionuclide) with each component being critical for the successful development of the conjugate. Considerable efforts have been made in understanding the pharmacokinetics, pharmacodynamics, tissue distribution, metabolism and pharmacologic effects of these complex macromolecular entities. The purpose of this article is to discuss the properties and various structural components of antibody conjugates that influence their clinical pharmacology.
抗体偶联物的治疗原理是通过单克隆抗体与特定细胞表面抗原的结合及内化作用,将细胞毒素选择性地递送至肿瘤细胞,从而提高细胞毒素的治疗指数。抗体偶联物的关键结构和功能组分包括抗体、连接子和细胞毒素(化学物质或放射性核素),每个组分对于偶联物的成功研发都至关重要。在了解这些复杂大分子实体的药代动力学、药效动力学、组织分布、代谢及药理作用方面已付出了巨大努力。本文旨在探讨影响抗体偶联物临床药理学的性质及各种结构组分。